Antimicrobial resistance is a $100T problem.

Aikya connects fragmented global evidence to always-on agentic infrastructure, optimising drug discovery and bridging the laboratory funding gap to secure a pool of promising assets for long-term human safety.

Asset Exchange Active: 4 new compounds ready for agentic validation.